{"organizations": [], "uuid": "4d482eafa85767f4a29140e278ff1683c8f6c1e3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.pharmamedtechbi.com", "main_image": "", "site_section": "http://feeds.feedburner.com/PharmaBiotechFinancing", "section_title": "Pharma/Biotech Financing From Elsevier Business Intelligence", "url": "https://www.pharmamedtechbi.com/deals/201530621?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "country": "IL", "title": "Avitide closes $7.7mm Series C round", "performance_score": 0, "site": "pharmamedtechbi.com", "participants_count": 0, "title_full": "Avitide closes $7.7mm Series C round", "spam_score": 0.0, "site_type": "news", "published": "2015-08-11T02:40:00.000+03:00", "replies_count": 0, "uuid": "4d482eafa85767f4a29140e278ff1683c8f6c1e3"}, "author": "", "url": "https://www.pharmamedtechbi.com/deals/201530621?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "ord_in_thread": 0, "title": "Avitide closes $7.7mm Series C round", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Avitide closes $7.7mm Series C round Deal Date: Aug-01-2015 / Deal # 201530621 Executive Summary \nAvitide Inc. (bioprocess affinity chromatography resins used in biopharmaceutical manufacturing) raised $7.7mm in Series C financing from 11 investors led by NeoMed Management, which contributed a board member, plus returning shareholders Polaris Partners, OrbiMed Advisors, SV Life Sciences, and Borealis Ventures. Avitide will use the money to commercialize its affinity purification technology; the company expects to be profitable within two years.", "external_links": [], "published": "2015-08-11T02:40:00.000+03:00", "crawled": "2015-08-11T14:50:05.610+03:00", "highlightTitle": ""}